Compare Abeona Therapeutics Inc (ABEO) vs MONDELEZ INTERNATIONAL INC Common Stock (MDLZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abeona Therapeutics Inc vs MONDELEZ INTERNATIONAL INC Common Stock — how do they compare? Abeona Therapeutics Inc trades at $7.34 (market cap $421.19M), while MONDELEZ INTERNATIONAL INC Common Stock trades at $61.57 (market cap $78.85B). The key difference: MONDELEZ INTERNATIONAL INC Common Stock is far larger — about 187.2× Abeona Therapeutics Inc's market cap, and MONDELEZ INTERNATIONAL INC Common Stock pays a 3.24% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | MDLZ | |
|---|---|---|
Market Cap | $421.19M | $78.85B |
Sector | Health | Consumer Staples |
52-Week High | $7.45 | $64.99 |
52-Week Low | $4.17 | $51.51 |
Enterprise Value | $276.10M | $99.19B |
Dividend Yield | — | 3.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $7.365, down 1.14% today, amid a bullish technical outlook with moving averages signaling strength. The company reported a net income of $71.18 million in 2025, with a net margin of 454.86%, though revenue remains modest at $5.82 million. Recent news includes CMS granting NTAP status for ZEVASKYN and expanding its treatment center network, indicating commercial progress.
The outlook is supported by strong analyst consensus (66.7% buy ratings) and robust profitability metrics, but risks include high SG&A expenses relative to revenue and a shareholder investigation. Upside hinges on revenue scaling to justify current valuations, with the Q2 2026 earnings call on August 13, 2026, as a key near-term catalyst.
MDLZ trades at $61.53, down 1.72% today, with a bullish technical outlook supported by moving averages and oversold RSI signals. The company reported strong Q2 2026 earnings, beating estimates with $0.73 EPS and raising organic sales guidance, driven by growth in emerging markets. Valuation ratios like P/E of 37.75 and P/S of 4.01 reflect premium pricing, while profitability remains solid with an 8.86% net income margin.
The stock offers upside to the $70.50 consensus price target, supported by analyst optimism and institutional buying, but faces risks from reliance on international sales and margin pressures. Earnings momentum and dividend stability provide a favorable outlook, though macroeconomic volatility could challenge growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About MONDELEZ INTERNATIONAL INC Common Stock
Mondelez has operated as an independent organization since its split from the former Kraft Foods North American grocery business in October 2012. The firm is a leading player in the global snack arena with a presence in the biscuit (47% of sales), chocolate (32%), gum/candy (10%), beverage (4%), and cheese and grocery (7%) aisles. Mondelez's portfolio includes well-known brands like Oreo, Chips Ahoy, Halls, Trident, and Cadbury, among others. The firm derives around one third of revenue from developing markets, nearly 40% from Europe, and the remainder from North America.
Read more on MDLZ →
